

Reference: FOI 40615 BUCKS 14Y

Subject: Primary Care Rebate Schemes

I can confirm that the CCG does hold the information requested; please see responses below:

QUESTION	RESPONSE
I would like to request the following information with regards to Primary Care Rebate Schemes that have been signed by your CCG/ Board in the past 12 months.	
1. Are there any Primary Care rebates signed for any of the following products? If so, which ones: a. Insulins (basal, bolus and premix) b. GLP-1 (i.e Trulicity) c. DPP-IV (i.e Januvia or Onglyza) d. SGLT-2 (i.e. Inovkana) e. Growth Hormones (norditopin; omnitrope; Genotropin, humatrope; nutropinAq; Saizen)	Agreement/Provider
	Drug name (Prescipp (P) / (I)
	Company/Org
	Agreement start date
	Agreement finish date
	Insuman (P)
	Novorapid (I)
	Apidra (P)
	Toujeo (I)
	AirFLuSal (P)
2. What are the start and finish dates (or ongoing if open ended)?	Please see above
3. Which rebates are independent? Or are they aligned to PresQIPP?	Please see above
4. What is the total number of primary rebate schemes (any included) that your CCG/Board has signed?	10

The information provided in this response is accurate as of 10 February 2022 and has been authorised for release by Robert Majilton, Deputy Chief Officer and Director of Sustainability & Transformation for NHS Buckinghamshire CCG.